CDXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Codexis's tax expense for the months ended in Dec. 2023 was $0.04 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.07 Mil.
The historical data trend for Codexis's Tax Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Codexis Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Tax Expense | Get a 7-Day Free Trial | 0.02 | 0.34 | 0.19 | 0.28 | 0.07 |
Codexis Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Tax Expense | Get a 7-Day Free Trial | 0.15 | 0.02 | 0.01 | 0.01 | 0.04 |
Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.
Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Codexis (NAS:CDXS) Tax Expense Explanation
In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.
Thank you for viewing the detailed overview of Codexis's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Byron L Dorgan | director | C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Kevin Norrett | officer: Chief Operating Officer | C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404 |
Margaret Nell Fitzgerald | officer: See Remarks | ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070 |
Sriram Ryali | officer: Chief Financial Officer | C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306 |
Stephen George Dilly | director, officer: See Remarks | C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404 |
John J Nicols | director, officer: President and CEO | ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801 |
H Stewart Parker | director | |
Rahul Singhvi | director | 246 HOLLY DRIVE, CHALFONT PA 18914 |
Dennis P Wolf | director | 1101 EAST MEADOW DR, PALO ALTO CA 94303 |
Patrick Y Yang | director | C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990 |
Bernard J Kelley | director | |
Esther Martinborough | director | C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Jennifer Aaker | director | C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Alison Moore | director | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Thomas R Baruch | director | 1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129 |
From GuruFocus
By sperokesalga sperokesalga • 02-27-2023
By Marketwired • 09-07-2023
By sperokesalga sperokesalga • 06-09-2023
By Marketwired • 10-26-2023
By sperokesalga sperokesalga • 05-08-2023
By sperokesalga sperokesalga • 02-09-2023
By GuruFocus Research • 09-13-2023
By sperokesalga sperokesalga • 02-15-2023
By Marketwired • 09-18-2023
By Marketwired • 10-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.